Status:
COMPLETED
Efficacy and Safety of Varenicline Among HIV-infected Patients
Lead Sponsor:
ANRS, Emerging Infectious Diseases
Collaborating Sponsors:
Pfizer
Conditions:
HIV Infections
Tobacco Dependence
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Cigarette smoking is a major cause of illness among HIV-infected patients (non-AIDS defining malignancies (especially lung cancer), non-AIDS bacterial infections and cardio-vascular diseases). Approxi...
Detailed Description
Cigarette smoking is a major cause of illness among HIV-infected patients (non-AIDS defining malignancies (especially lung cancer), non-AIDS bacterial infections and cardio-vascular diseases). Approxi...
Eligibility Criteria
Inclusion
- HIV-infected patients
- adults
- regular smokers (at least 10 cigarettes a day during the last year)
- motivated to stop smoking
- followed in one of the participating clinical ward,
- signed written inform consent
Exclusion
- current co-dependency to another psychoactive substance
- ongoing depressive episode
- history of suicidal attempt
- ongoing treatment by interferon
- treatment by efavirenz for less than three months or not tolerated
- previous use of varenicline
- ongoing treatment by bupropion-SR or nicotinic substitute
- ongoing pregnancy
- ongoing breastfeeding
- hypersensitivity to varenicline or to one of its excipients
- drivers, air traffic controller
Key Trial Info
Start Date :
October 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2014
Estimated Enrollment :
248 Patients enrolled
Trial Details
Trial ID
NCT00918307
Start Date
October 1 2009
End Date
July 1 2014
Last Update
July 29 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Bordeaux
Bordeaux, France, 33075